← Companies|Nippon Shinyaku
45

Nippon Shinyaku

4516.T·TSEKyoto JPFounded 19193,000 employees
Mid CappharmaPublicRare DiseaseHematology
Platform: Viltolarsen DMD
Market Cap
$4B
All Drugs
3
Clinical Trials
8
Failed / Terminated
2
FDA Approved
1
Stock Price & Catalysts (4516.T)
Loading 4516.T stock data...
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
Bemarapivir451-5291Phase 2/32Gene TherapyFXIaSHP2iCSU
Mirifotisoran451-1125Approved4RadioligandBETEGFRiPSPCML
451-4283451-4283Phase 22ERTC5BiTEADHDHCC
SEC Filings & Financial Documents
SEC filings are not available for TSE-listed companies.
Nippon Shinyaku trades on TSE (JP). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (8)
2025-11-03
Bemarapivir Enrollment Complete
CSU
Past
2026-08-09
Mirifotisoran Ph3 Readout
CML
Ph3 Readout
2026-08-25
451-4283 Ph2 Data
ADHD
Ph2 Data
2027-03-12
Bemarapivir Ph3 Readout
CSU
Ph3 Readout
2028-01-04
Bemarapivir Ph3 Readout
CSU
Ph3 Readout
2028-05-17
Mirifotisoran Ph3 Readout
PSP
Ph3 Readout
2028-08-24
Mirifotisoran Ph3 Readout
CML
Ph3 Readout
2029-10-11
451-4283 Ph2 Data
HCC
Ph2 Data